Pharmaceutical Excipients Market Assessment, By Type [Inorganic Chemicals and Organic Chemicals], By Functionality [Binders and Adhesives, Fillers and Diluents, Coating Material, Flavoring Agent, Disintegrants, Coloring Agents, Preservatives, Buffers, Oth

Pharmaceutical Excipients Market Assessment, By Type [Inorganic Chemicals and Organic Chemicals], By Functionality [Binders and Adhesives, Fillers and Diluents, Coating Material, Flavoring Agent, Disintegrants, Coloring Agents, Preservatives, Buffers, Others], By End-user [Pharmaceutical Companies, Research Organization and Academics, Others], By Region, Opportunities and Forecast, 2017-2031F

Global pharmaceutical excipients market is projected to witness a CAGR of 7% during the forecast period 2024-2031F, growing from USD 11.11 billion in 2023 to USD 19.08 billion in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Various factors, such as the increasing prevalence of chronic diseases among the global population and a rising geriatric population drive growth in the global pharmaceutical excipients market. Growing demand for generic drugs, along with increased investment and research and development activities by public and private firms, leads to the growth of this market. Moreover, a favorable regulatory system, the presence of several top players and collaborative venture activities, new entrants, and frequent new product launches accelerate the growth of the global pharmaceutical excipients market.

The global pharmaceutical excipients market is undergoing robust growth, primarily due to the increased prevalence of chronic and infectious diseases among the global population. The rising aging population increases the probability of being affected by chronic or infectious conditions due to lack of immunity, further accelerating demand for pharmaceutical products such as excipients for treating these diseases. Growth in the pharmaceutical industry and increasing demand for generic drugs to cater to the increasing demand for pharmaceutical products leads to increasing interest among pharmaceutical companies in investing in drug discovery using pharmaceutical excipients. Increased research and development activities by market players to develop new efficient pharmaceutical excipients, favorable regulatory frameworks, and frequent product launches by the market players play a pivotal role in enhancing the global pharmaceutical excipients market. Moreover, consistent collaboration activities such as mergers and acquisitions, partnerships, and distribution agreements between the organizations further propel the global pharmaceutical excipients market. For instance, in November 2023, IFF’s and BASF’s pharma solutions divisions announced a collaboration to bring IFF’s leading pharmaceutical excipients brands on BASF’s “ZoomLab”, a virtual pharma assistant platform. This platform enables the researchers to predict and analyze the suitable excipients required for developing new pharmaceutical formulations and assists in overcoming formulation challenges.

Increase in Prevalence of Chronic Diseases

The demand for pharmaceutical excipients is increasing significantly due to the rising prevalence of chronic diseases. The increasing aging population is responsible for the onset of several chronic health conditions such as cardiovascular diseases, cancer, and diabetes. These chronic diseases are fatal and need cost-effective solutions to treat these diseases. According to WHO 2023 statistics, chronic diseases are the most common diseases affecting people from all over the world and are responsible for 41 million deaths every year worldwide. A sedentary lifestyle, unhealthy diet, obesity, excessive tobacco, and alcohol consumption are the leading risk factors for the rising prevalence of chronic diseases among the population. Pharmaceutical excipients are crucial in optimizing drug delivery formats and developing safe and cost-effective drugs. Moreover, key market players are consistently investing in developing innovative and efficient pharmaceutical excipients to cater to the needs of this growing population suffering from chronic health conditions. This is further accelerating the growth of the global pharmaceutical excipients market.

Increasing Demand for Generic Drugs

With the growing prevalence of chronic and infectious diseases worldwide, there is a huge demand for affordable medicines to cater to the needs of the growing diseased population. Pharmaceutical excipients play a significant role in developing cost-effective and safe generic drugs. As a result, the demand for pharmaceutical excipients is also increasing among the pharmaceutical manufacturers. Several leading pharmaceutical companies are consistently involved in the manufacturing of generic drugs. For instance, Teva Pharmaceutical Industries Ltd., which is a global leader in the pharmaceutical industry states that worldwide, around 200 million people take one of their generic medicines every day and a significant portion of the company’s research and development budget is focused on developing generic medicines. This growing interest of the major players in investment activities in generic drugs is anticipated to propel the global pharmaceutical excipients market growth.

Pharmaceutical Companies Hold a Significant Market Share

Based on end-user, the pharmaceutical companies hold a significant share due to frequent product launches by the leading pharmaceutical companies. Furthermore, collaboration ventures such as mergers and acquisitions, and partnership agreements lead to faster growth of the pharmaceutical companies in this market. For instance, in July 2023, Roquette, a strong global player in naturally derived pharmaceutical excipients, announced the acquisition of Qualicaps, a Japan-based pharmaceutical company and the third-largest producer of hard capsules for oral dosage solutions. This strategic acquisition is expected to expand Roquette’s global reach and enhance its business of pharmaceutical excipients. These frequent collaboration ventures among pharmaceutical companies bring innovation and advancements in pharmaceutical excipients and drive market growth.

Fillers and Diluents Segment Holds a Significant Market Share

Based on functionality, the fillers and diluents segment holds a significant market share in this market. Pharmaceutical excipient's functionality as a filler plays several important roles during drug formulations, especially in tablet and capsule production. Excipients as a fillers play an essential part in adding bulk to the formulations when the active ingredients are too small. For instance, in October 2023, Roquette, which is a market leader in developing pharmaceutical excipients announced the launch of three new pharmaceutical excipients named “LYCATAB CT-LM” partially pregelatinized starch, “MICROCEL 103 SD” and “MICROCEL 113 SD” microcrystalline cellulose. These excipients are multifunctional, offering functionalities such as binding, filler, and disintegrant that help in the development of drugs.

Asia-Pacific is Expected to be the Fastest Growing Region

Asia-Pacific region is expected to be the fastest-growing region in the global pharmaceutical excipients market. Rapidly increasing population and growing prevalence of chronic and infectious diseases in this region accelerate the demand for pharmaceutical products such as excipients, to improve drug discovery and enhance medical facilities. Asia-Pacific is an emerging market that has huge potential in the pharmaceutical industry, due to which key market players are continuously developing partnership collaborations and establishing operational facilities in this region to expand their business and enhance the overall growth of this market globally. For instance, in February 2022, Azelis, a global leading manufacturer of specialty chemicals, announced the expansion of its pharmaceutical business in India by signing a distribution agreement with Roquette, which is a global leader in providing pharmaceutical excipients. This distribution agreement will strengthen Azelis global footprint, and flourish the pharmaceutical excipients industry in Asia-Pacific.

Future Market Scenario (2024–2031F)

The global pharmaceutical excipients market is expected to grow in the future, due to several factors. Primarily, the increasing prevalence of chronic and infectious diseases is accelerating the demand for pharmaceutical products including excipients in the healthcare sector to provide safe and effective medicines. The growing generic drugs market, along with increased research and development activities by public and private organizations to develop efficient and cost-effective generic drugs by using excipients led to the growth of the global pharmaceutical excipients market. Additionally, frequent product launches, collaboration activities, and new entrants in this market are expected to drive market growth in the forecast period. For instance, in September 2023, IFF’s Pharma Solutions announced the launch of leading excipient products such as low nitrite excipient solutions for the pharmaceutical industry. These consistent innovative product launches are expected to accelerate growth in this market.

Key Players Landscape and Outlook

In the pharmaceutical excipients market, several pharmaceutical companies are consistently involved in collaboration activities such as establishing strategic partnerships and undergoing distribution agreements, which play an essential role in propelling the global pharmaceutical excipients market's growth. These partnerships enable companies to gain informative insights on the market trends, access each other’s knowledge, resources, markets, and technologies, and invest in research and development activities to bring highly efficient and cost-effective pharmaceutical products such as excipients to the market. Distribution agreements enable companies to broaden their market presence at a global level. These collaborative ventures promote innovation, expedite product development, and contribute to the enduring and robust growth of the global market. For instance, in May 2023, Croda International Plc. announced that it has signed an exclusive license agreement with Amyris to supply biotechnology-derived “squalene” as an excipient to be used for various purposes such as vaccine development, drug delivery systems, or nucleic acid delivery systems. Amyris is a worldwide leading synthetic biology company, which will expedite the commercialization of squalene products to the global market, which will further assist in elevating the global pharmaceutical excipients market.